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We present major results concerning isolation and determination of the nucleotide sequence of hemagglutinin
(HA1) of the pandemic (H1N1)pdm09 influenza viruses found in Tunisia. Amino acid analysis revealed minor amino
acid changes in the antigenic or receptor-binding domains. We found mutations that were also present in 1918
pandemic virus, which includes S183P in 4 and S185T mutation in 19 of 27 viruses analyzed from 2011, while none
of the 2009 viruses carried these mutations. Also two specific amino acid differences into N-glycosylation sites
(N288T and N276H) were detected. The phylogenetic analysis revealed that the majority of the Tunisian isolates
clustered with clade A/St. Petersburg/27/2011 viruses characterized by D97N and S185T mutations. However it also
reveals a trend of 2010 strains to accumulate amino acid variation and form new phylogenetic clade with three
specific amino acid substitutions: V47I, E172K and K308E.
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The incidence of recurring epidemics is primarily attrib-
uted to the high frequency of mutational changes in the
hemagglutinin (HA) and neuraminidase (NA) major sur-
face glycoproteins. The hemagglutinin protein, responsible
for viral uptake into host epithelial cells, is also the antigen
targeted by antibodies. The hemagglutinin, a trimeric sur-
face glycoprotein that binds the viral receptor and pro-
motes fusion and penetration from low-pH endosomes, is
the principal surface antigen on influenza virions [1]. HA
presents conserved and variable epitopes, but neutralizing
antibodies against the latter dominate the response to
immunization and infection [2]. The HA1 subunit of the
H1N1 hemagglutinin protein consists of the globular head
and contains four major antibody binding sites: Sa, Sb,
Ca1, and Ca2, [3,4]. There are determined on the basis of
the assessment of antigenic variations of virus mutants
[5,6]. Mutational changes (antigenic drift) at these four sites
are thought to be driven by selective antibody pressure,* Correspondence: awatefbio@ymail.com
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reproduction in any medium, provided the orwhich can produce novel strains capable of evading the
immunologic response. Because of the high morbidity
and mortality due to influenza epidemics, monitoring of
the accumulated antigenic variations in circulating in-
fluenza viruses is important for predicting epidemics,
severity, and for the design of future vaccines [7]. Glyco-
sylation at antigenic sites is an important mechanism of
immune evasion by influenza virus [2,8,9]. In fact, the
well-known seasonal drift of influenza virus antigenicity
accounts for the absence of long-term immune protec-
tion in previously infected individuals. In this study we
try to present major mutation found in Tunisian pan-
demic strains.Materials and methods
Sources of specimens
Between May 2009 and January 2011, influenza throat swab
specimens were collected from patient in the sentinel
centre and patient hospitalized in the hospital in different
region in Tunisia. The criteria included patients with a
fever >37.8°C accompanied by cough or sore throat.
Throat swabs were taken within 72 hours of the onset
of symptoms, placed in viral transport media (Vircell,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Strain information of Tunisian influenza A (H1N1)pdm09 positive samples used in this study
Tunisian strains of inf A (H1N1)pdm09 Date of sampling Accession number (GenBank) Clinical information
A/Tunisia/59/2009 24/12/2009 JN037736 Severe case
A/Tunisia/13391/2009 26/09/2009 JN037716 Mild case
A/Tunisia/15656/2009 27/10/2009 JN037717 Severe case
A/Tunisia/16501/2009 06/11/2009 JN037718 Severe case
A/Tunisia/17053/2009 12/11/2009 JN037719 Severe case
A/Tunisia/18792/2009 25/11/2009 JN037720 Severe case
A/Tunisia/18861/2009 25/11/2009 JN037721 Fatal case
A/Tunisia/18970/2009 25/11/2009 JN037722 Mild case
A/Tunisia/19073/2009 02/12/2009 JN037723 Severe case
A/Tunisia/19112/2009 03/12/2009 JN037724 Fatal case
A/Tunisia/19436/2009 07/12/2009 JN037725 Mild case
A/Tunisia/19530/2009 08/12/2009 JN037726 Mild case
A/Tunisia/19703/2009 11/12/2009 JN037727 Mild case
A/Tunisia/19922/2009 12/12/2009 JN037728 Severe case
A/Tunisia/19966/2009 11/12/2009 JN037729 Severe case
A/Tunisia/20043/2009 12/12/2009 JN037730 Mild case
A/Tunisia/20083/2009 12/12/2009 JN037731 Mild case
A/Tunisia/20108/2009 13/12/2009 JN037732 Mild case
A/Tunisia/20112/2009 14/12/2009 JN037733 Severe case
A/Tunisia/20558/2009 15/12/2009 JN037734 Severe case
A/Tunisia/21001/2009 23/12/2009 JN037735 Fatal case
A/Tunisia/21516/2009 30/12/2009 HQ174255 Mild case
A/Tunisia/1064/2010 18/01/2010 HM590676 Fatal case
A/Tunisia/197/2011 04/01/2011 CY080589 Mild case
A/Tunisia/200/2011 04/01/2011 JN037748 Severe case
A/Tunisia/217/2011 06/01/2011 JN037755 Mild case
A/Tunisia/331/2011 07/01/2011 JN037758 Severe case
A/Tunisia/422/2011 07/01/2011 CY080590 Severe case
A/Tunisia/755/2011 20/01/2011 JN037759 Mild case
A/Tunisia/757/2011 20/01/2011 JN037761 Mild case
A/Tunisia/932/2011 26/01/2011 JN037760 Severe case (care unit)
A/Tunisia/1010/2011 28/01/2011 JN037737 Severe case
A/Tunisia/1011/2011 28/01/2011 JN037738 Severe case (care unit)
A/Tunisia/1060/2011 28/01/2011 JN037739 Severe case
A/Tunisia/1198/2011 02/02/2011 JN037740 Severe case
A/Tunisia/1411/2011 07/02/2011 JN037741 Mild case
A/Tunisia/1423/2011 07/02/2011 JN037742 Severe case
A/Tunisia/1909/2011 12/02/2011 JN037747 Severe case
A/Tunisia/1870/2011 14/02/2011 JN037746 Mild case
A/Tunisia/1871/2011 18/02/2011 JN037747 Mild case
A/Tunisia/1701/2011 10/02/2011 JN037743 Severe case (care unit)
A/Tunisia/1713/2011 10/02/2011 JN037744 Mild case
A/Tunisia/2133/2011 19/02/2011 JN037749 Severe case
A/Tunisia/2137/2011 19/02/2011 JN037750 Severe case (care unit)
A/Tunisia/2139/2011 21/02/2011 JN037751 Severe case (care unit)
A/Tunisia/2140/2011 21/02/2011 JN037752 Severe case
A/Tunisia/2141/2011 21/02/2011 JN037753 Severe case
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Table 1 Strain information of Tunisian influenza A (H1N1)pdm09 positive samples used in this study (Continued)
A/Tunisia/2144/2011 22/02/2011 JN037754 Severe case
A/Tunisia/2210/2011 21/02/2011 JN037756 Severe case
A/Tunisia/2222/2011 21/02/2011 JN037757 Severe case
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microbiology laboratory of Charles Nicolle’s Hospital Tunis.
Sequencing of viral RNA genome
Viral RNA was extracted from 140 μl of clinical sample
using the QIAmp Viral RNA Mini kit® (QIAGEN). In
order to detect and assign the A(H1N1)pdm09 strains
isolated from patients, a real-time PCR assay was used
CDC protocol [10]. A representative number of influenza
viruses were genotypically characterized by analysis of
the nucleotide sequence of partial haemagglutinin HA1
chain (931 nucleotide residues). All viruses analysed were
amplified and sequenced according to the protocol of
National Influenza Centre Madrid [11]. Mega 4.0 software
[12] was used to analyze variations in antigenic sites,
virulence-related sites, and glycosylation sites of influenza
A (H1N1)pdm09 viruses. Analysis of the phylogenetic
relationship was based on nucleotide sequences of HA
of the isolated viruses and carried out by the maximum-
likelihood method against sequences from global iso-
lates. The evolutionary history was inferred by using the
maximum likelihood method based on the Kimura two-
parameter model [13]. Sequences generated in this study
were deposited in the Genbank database with accession
numbers: JN037716– JN037761.
Results
Amino acid variations in antigenic sites
Amino acid alignment of the HA of Tunisian isolates in
2009–2010 and 2010–2011 seasons against global iso-
lates was performed, and the results are summarized
in Table 1. Minor changes were seen at positions
L32F, K36R, N38D, R45K, V47I, S71Y/F, S74N, S84N, D86G/N,
I96T, E103K, R113K, F114V, K160R, K171R, E172K, T270A,
N276H, N294K/S, P297S, I300N, P304Q, K308E, A315S, and
G317R (Table 2). Among these amino acid differences,
H138Q, S203T, R205K, D222G, S162I, S183P, and
S185T substitutions were located within the antigenic
HA1 sites (Ca1, Ca2, Sa, and Sb) (Table 3) in several
Tunisian sequences studied. The highest number of
variations in predicted antigenic sites were observed
in Ca1, where S203T was observed in 46 out of 50
(92%) viruses analyzed and R205K in 10 out of 50 vi-
ruses (20%). Analysis of other positions of antigenic
sites revealed that Ca1 (H138Q) with 1% substitution,
and Sa where S162I (1%) to be highly conserved.
Whereas Ca2 had a substitution (D222G/E) in 4 out
of 50 (8%).Several signature amino acids found in 1918-like viruses
were observed in sequence data analyzed. Two additional
mutations similar to 1918-like virus emerged in 2011 only:
Proline at position 183 in four virus sequences from 2011
season (Table 2); and threonine at position 185 in 19
sequences only from 2011 season.
The most common variation compared to the vaccine
strain was P83S, which was actually observed in almost
of the Tunisian isolates (96%). Furthermore, a high pro-
portion, 98%, of Tunisian strains possessed the variation
I321V. It was observed that the remaining virus that
retained isoleukine at this position was associated with
severe illness, patient developed pneumonia. Most im-
portantly, it was one strain, A/Tunisia/15656/2009 with
altered N-linked glycosylation site, due to variation N276H.
All but one of the pandemic viruses had retained all the
potential 6 N-glycosylation sites. The one exception
(A/Tunisia/15656/2009) had lost a glycosylation site with
a change at amino acid residue 276 from asparagine (N)
to histidine (H).
It was an alteration to preexisting glycosylation site,
and none of the Tunisian isolates gained new glycosyla-
tion sites. Moreover, It was one strain, A/Tunisia/2144/
2011 showed a switch into N-linked glycosylation site
(T288N), associated with severe pneumonia. Interestingly,
this case has got three more substitutions in the antigenic
sites (S203T, S162I and S183P). Another interesting strain,
A/Tunisia/1423/2011 contained three substitutions (H138Q,
S203T and R205K). This strain was associated with a
severe pneumonia in pregnant woman.
Moreover, three viruses possessed the previously iden-
tified D222G/E mutation at the Ca2 antigenic site of the
HA. Interestingly, three out of four patients with the
D222G mutation (75%), suffered from pneumonia and
were hospitalized. One of those infections was fatal
(33.33%). However, this mutation was also detected in
one virus that caused mild illness (25%).
Phylogentic analysis of H1N1pdm09 viruses from 2009
and 2011
To understand the genetic diversity of influenza A
(H1N1)pdm09 in Tunisia, sequencing of 50 HA1 regions
of isolates collected in either 2009–2010 season (n = 23)
and 2010–2011 season (n = 27) was undertaken (Table 1).
Tunisian strains were compared to that of the vaccine
strain A/California/7/09 (H1N1) and a number of varia-
tions were detected. Substitutions are mentioned in detail
in Table 2 and Table 3. Phylogenetic analysis of the HA1
Table 2 Amino acid change summary of Tunisia H1N1pdm09 isolates from 2009 and 2011 seasons
Virus strains of influenza
(H1N1)pdm09
Residue position in HA (without signal peptide)
32 36 38 45 47 71 74 84 86 96 103 113 114 160 171 270 276 288 294 297 300 304 308 315 317
A/California/07/2009 L K N R V S S S D I E R F K K T N N N P I P K A G
A/TUNISIA/21001/2009 F - - - - - - - - - - - - - - - - - - - - - - - -
A/TUNISIA/16501/2009 - R - - - Y - - - - - - - R - - - - K - - - - -
A/TUNISIA/20558/2009 - - D - - - - - G - - - - - - - - - - - - - - -
A/TUNISIA/2210/2011 - - - K - - - - - - - - - - - - - - - - - - - - -
A/TUNISIA/331/2011 - - - K - - - - - - - - - - - - - - - - - - - - -
A/TUNISIA/197/2011 - - - - I - - - - - - - - - - - - - - - - - E - -
A/TUNISIA/200/2011 - - - - I - - - - - - - - - - - - - - - N - E - -
A/TUNISIA/1713/2011 - - - - - F - - - - - - - - - - - - - - - - - - -
A/TUNISIA/2144/2011 - - - - - - N - - - - - - - - - - T - - - - - - -
A/TUNISIA/1011/2011 - - - - - - N - - - - - - - - - - - - - - - - - -
A/TUNISIA/2140/2011 - - - - - - - N - - - - - - - - - - - - - - - - -
A/TUNISIA/19966/2011 - - - - - - - - G - - - - - - - - - - - - - - -
A/TUNISIA/20108/2009 - - - - - - - - N - - - - - - - - - - - - - - -
A/TUNISIA/422/2011 - - - - - - - - - T - - - - - - - - - - - - - - -
A/TUNISIA/1060/2011 - - - - - - - - - T - - - - - - - - - - - - - - -
A/TUNISIA/20108/2009 - - - - - - - - - - K - - - - - - - - - - - - -
A/TUNISIA/1701/2011 - - - - - - - - - - - K V - - A - - - - - - - - -
A/TUNISIA/2137/2011 - - - - - - - - - - - - V - - - - - - - - - - - -
A/TUNISIA/2133/2011 - - - - - - - - - - - - V - - - - - - - - - - - -
A/TUNISIA/1010/2011 - - - - - - - - - - - - - - R - - - - - - - - - -
A/TUNISIA/1411/2011 - - - - - - - - - - - - - - - A - - - - - - - - -
A/TUNISIA/15656/2009 - - - - - - - - - - - - - - - - H - - - - - - -
A/TUNISIA/20043/2009 - - - - - - - - - - - - - - - - - - S - - - - -
A/TUNISIA/20112/2009 - - - - - - - - - - - - - - - - - - - S - - - -
A/TUNISIA/1011/2011 - - - - - - - - - - - - - - - - - - - - N - - - -
A/TUNISIA/217/2011 - - - - - - - - - - - - - - - - - - - - - Q - - -
A/TUNISIA/2222/2011 - - - - - - - - - - - - - - - - - - - - - Q - - -
A/TUNISIA/1064/2010 - - - - - - - - - - - - - - - - - - - - - - - S -
A/TUNISIA/17053/2009 - - - - - - - - - - - - - - - - - - - - - - - S -


















Virus strains HA1 Ca1 Ca2 Sa Sb N-glycosylation
321 138 203 205 222 162 183 185 288 276
A/California/07/2009 I H S R D S S S T N
A/Tunisia/59/2009 - - - - - - - - - -
A/Tunisia/15656/2009 V - - - - - - - - H
A/Tunisia/16501/2009 V - T - - - - - - -
A/Tunisia/17053/2009 V - T - - - - - - -
A/Tunisia/18792/2009 V - T - - - - - - -
A/Tunisia/18861/2009 V - T K - - - - - -
A/Tunisia/18970/2009 V - - - - - - - - -
A/Tunisia/19073/2009 V - T - - - - - - -
A/Tunisia/19112/2009 V - T - - - - - - -
A/Tunisia/19436/2009 V - T - - - - - - -
A/Tunisia/19530/2009 V - T - - - - - - -
A/Tunisia/19703/2009 V - T - - - - - - -
A/Tunisia/19922/2009 V - T - - - - - - -
A/Tunisia/19966/2009 V - T - - - - - - -
A/Tunisia/20043/2009 V - T - - - - - - -
A/Tunisia/20083/2009 V - - - - - - - - -
A/Tunisia/20108/2009 V - T - - - - - - -
A/Tunisia/20112/2009 V - T - E - - - - -
A/Tunisia/20108/2009 V - T - - - - - - -
A/Tunisia/20558/2009 V - T - - - - - - -
A/Tunisia/21001/2009 V - T - - - - - - -
A/Tunisia/21516/2009 V - T - - - - - - -
A/Tunisia/1064/2010 V - T K G - - - - -
A/Tunisia/197/2011 V - T - - - - - - -
A/Tunisia/200/2011 V - T - - - - - - -
A/Tunisia/217/2011 V - T K - - - - - -
A/Tunisia/331/2011 V - T - - - - T - -
A/Tunisia/422/2011 V - T - - - P - - -
A/Tunisia/755/2011 V - T K - - - T - -
A/Tunisia/757/2011 V - T K - - - T - -
A/Tunisia/932/2011 V - T - - - - T - -
A/Tunisia/1010/2011 V - T - - - - T - -
A/Tunisia/1011/2011 V - T - - - P - - -
A/Tunisia/1060/2011 V - T - - - P - - -
A/Tunisia/1198/2011 V - T K - - - T - -
A/Tunisia/1411/2011 V - T - G - - T - -
A/Tunisia/1423/2011 V Q T K - - - - - -
A/Tunisia/1909/2011 V - T - - - - T - -
A/Tunisia/1871/2011 V - T K - - - T - -
A/Tunisia/1870/2011 V - T - - - - T - -
A/Tunisia/1713/2011 V - T K - - - T - -
A/Tunisia/1701/2011 V - T - G - - T - -
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Table 3 Dynamic changes of amino acid residues at antigenic and N- glycosylation sites of influenza A(H1N1)pdm09-HA
in Tunisia (Continued)
A/Tunisia/1713/2011 V - T - - - - - - -
A/Tunisia/2133/2011 V - T - - - - T - -
A/Tunisia/2137/2011 V - T - - - - T - -
A/Tunisia/2139/2011 V - T K - - - T - -
A/Tunisia/2140/2011 V - T - - - - T - -
A/Tunisia/2141/2011 V - T - - - - T - -
A/Tunisia/2144/2011 V - T - - I P - N -
A/Tunisia/2210/2011 V - T - - - - T - -
A/Tunisia/2222/2011 V - T - - - - T - -
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A(H1N1)pdm09 viruses during the season 2010–2011
could be differentiated into eight different and independ-
ent genetic groups (Figure 1). This analysis revealed that
the Tunisian strains studied were into four clades out
of eight defined in the last ECDC report. Moreover, it
revealed that the majority (19 of 27) of viruses analyzed
clustered with the HA of clade A/St. Petersburg/27/2011
viruses regardless of whether they were from 2011 charac-
terized by D97N and S185T, with additional mutations
in minor subclusters such as A186T, K205R and F114V.
In A/Astrakhan/1/2011 group we have two strains:
A/Tunisia/217/2011 and A/Tunisia/1423/2011 carried
D97N, R205K, I216V and V249L substitution. Into this
group one strain has an additional mutation H138Q.
Third group clustred into A/Hong Kong/3934/2011 clade
included four Tunisian strains characterized by A134T
and S183P mutations. And two specific mutations (S74N
and I96T) only showed in Tunisian viruses. Finally, Most
importance of this analysis showed two Tunisian viruses
clustred into a new Madrid/SO8171/2010 group defined
by E172K, K308E and V47I [14].
Discussion
Pandemics are believed to arise when a novel avian or
swine influenza HA and/or NA are acquired through
reassortment between human, swine, and avian influenza
viruses or by a non-human virus adapting to efficient hu-
man transmission [15]. The current pandemic H1N1pdm09,
which is the result of genetic reassortment of multiple
gene segments from different lineages, has a known evolu-
tionary history of about a century [16]. Thus, the unpre-
dictability of viral mutations that arise during continued
circulation in humans raises questions about antigenic
evolution and its impact on future severity of infection,
and on vaccine composition. We herein report the char-
acterization of 50 HA genes of the pandemic (H1N1)
pdm09 influenza viruses isolated in Tunisia between
September 2009 and February 2011, were analysed and
their phylogenetic relationships with references strains
were showed. We provide evidence that while overallthe viruses were fairly homogeneous; there are subtle
differences in predicted antigenic epitopes which are
potential targets of positive selection pressure.
We further compared the amino acid residues consti-
tuting the 7 antigenic sites of A/California/07/2009 with
those of the Tunisia isolates. Almost all residues were
highly conserved in the Tunisian isolates, however that
detailed characterization of the HA gene of H1N1pdm09
has identified some mutations in four antigenic sites
(Ca1, Ca2, Sa, and Sb) that are exposed for antibody
recognition [16]. The Ca site is proximal to the oligo-
saccharide at HA1 Asn87, which may interfere with
antibody recognition of this region. The sequence data
showed that amino acid substitutions were scattered at
different loci. However positions 114, 185, 203, 205,
222, and 321 appear the most variable as amino acid
residues at these positions vary more than once in the
viruses examined. In fact, Melidou et al. 2010 suggest
that the occurrence of 321I in severe cases could only
be an effect of changing frequency over time rather
than an association to severity [17]. An area of largely
conserved residues lies between amino acids 280 and
327 and represent part of the stalk structures that sup-
ports the globular region of HA1 [18]. Some changes
at different positions within the four antigenic domains
were observed in sequences from Tunisia. In fact, 11
out 17 (64.7%) Tunisian strains defined by an amino
acid change within the haemagglutinin (HA) gene at
position 185 (S185T) were from severe cases. Recently,
outbreaks varying in severity throughout the UK were
caused by a 2009 A(H1N1)pdm09 variant [19]. Analysis
of NCBI database sequences revealed the presence of
serine at position 183 among H1N1pdm09, while all
1918 (H1N1) viruses have proline at this position. Whether
substitution of serine at position 183 has reduced the
receptor-binding ability of the (H1N1)pdm09 virus resulting
in a less virulent phenotype remains to be determined.
It is important to note that 4 of the 2011 viruses from
Tunisian severe cases have acquired a proline at this
position, which, in combination with additional muta-
tions, could lead to altered pathogenicity [20].
Figure 1 (See legend on next page.)
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Figure 1 Phylogenetic relationship of partial length HA sequences of influenza A(H1N1)pdm09 viruses in Tunisia. The tree was rooted
with the vaccine strain A/California/07/2009 (boxed) as outgroup. Branch lengths are drawn to scale. Signature amino acid changes (H1 numbering)
are annotated at the nodes of each cluster.
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sites, observations were made on the number of N-
glycosylation sequons in the globular head region of the
HA. Since glycosylation can potentially affect the anti-
genic properties of influenza A virus, we analyzed the
changes in the potential N-linked glycosylation sites of
the pandemic virus strains. Potential N-glycosylation
sites are found in the HA molecule of the A/California/
07/2009 virus, six of which reside in the HA1 and the
remaining two in the HA2 region. In fact, the absence
of glycosylation may influence the function of the glyco-
protein, as it is involved in the protein folding, oligo-
merization, quality control, sorting and transport [17,21].
Among the Tunisian isolates, there were two strains that
had variations to glycosylation sites. A/Tunisia/15656/
2009 bared the substitution N276H that resulted to the
loss of a glycosylation site (NTT). And A/Tunisia/2144/
2011 possessed the variation T288N into the glycosyla-
tion site. D222G substitution in the HA gene, reported
for the first time in influenza A(H1N1)pdm09 virus on
November 2009 in Norway [22], has been found again
associated to severe patients during the winter 2011
[14]. In the present study, D222G change was detected
in 5.2% of severe patients analyzed, percentage similar
to that previously reported in 2009–2010 season in
Tunisia [23].
Of greater significance is the finding that two of the
viruses studied from 2011 shared the amino acid changes
V47I, E172K and K308E. In fact, since the genetic
characterization algorithms were established in 2010 for
pandemic H1N1pdm09 viruses, a new genetic group
characterized by these mutations, cited recently, in
Spanish study [14]. According to the last ECDC report
[24], eight genetic groups were presented whereas the
new genetic group reported in this study was indentified
as A/Madrid/SO8189/2010. Phylogenetic analysis of these
strains showed that, as expected, they belonged to the
same clade with the vaccine strain. Further antigenic
analysis is needed to assess the characteristics of the rest
of the circulating viruses, especially those that possessed
variations to antigenic and glycosylation sites of the HA.
However, on the 28th of December, WHO reported
that so far all of the circulating pandemic (H1N1) 2009
viruses are antigenically related to A/California/7/2009
[25]. Disease severity is difficult to assess, it can change
with different geographic contexts and under different
seasonal conditions and may alter as the virus adapts to
its new host. Our findings confirm the genetic instability
of influenza type A (H1N1) viruses and highlight theimportance of continuous molecular surveillance for the
effective management of influenza epidemics.
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